Cello Group PLC | Income Statement

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
159,671.00
169,866.00
157,315.00
165,266.00
169,292.00
165,573
Cost of Goods Sold (COGS) incl. D&A
87,532.00
91,346.00
72,642.00
74,575.00
69,023.00
62,831
Gross Income
72,139.00
78,520.00
84,673.00
90,691.00
100,269.00
102,742
SG&A Expense
63,944.00
71,432.00
76,271.00
82,342.00
88,078.00
90,518
EBIT
8,195.00
4,979.00
7,302.00
6,551.00
12,450.00
12,224
Unusual Expense
2,143.00
640.00
2,285.00
8,472.00
3,571.00
1,797
Non Operating Income/Expense
30.00
124.00
121.00
528.00
2,703.00
1,669
Interest Expense
574.00
430.00
387.00
304.00
360.00
340
Pretax Income
5,459.00
3,790.00
4,754.00
1,686.00
5,817.00
8,419
Income Tax
1,828.00
1,508.00
1,707.00
820.00
1,589.00
1,801
Consolidated Net Income
3,631.00
2,282.00
3,047.00
2,506.00
4,228.00
6,618
Net Income
3,634.00
2,283.00
3,042.00
2,506.00
4,228.00
6,618
Net Income After Extraordinaries
3,634.00
2,283.00
3,042.00
2,185.00
4,228.00
6,618
Net Income Available to Common
3,634.00
2,283.00
3,042.00
2,827.00
4,228.00
6,618
EPS (Basic)
0.04
0.03
0.04
0.03
0.04
0.06
Basic Shares Outstanding
82,444.90
84,548.20
86,023.40
87,565.70
103,373.40
105,592.30
EPS (Diluted)
0.04
0.03
0.03
0.03
0.04
0.06
Diluted Shares Outstanding
84,874.90
86,712.20
88,330.30
89,417.40
104,960.30
107,715.10
EBITDA
10,756.00
7,443.00
9,310.00
8,516.00
14,666.00
14,298
Other Operating Expense
-
2,109.00
1,100.00
1,798.00
259.00
-
Non-Operating Interest Income
11.00
5.00
3.00
11.00
1.00
1
Minority Interest Expense
3.00
1.00
5.00
-
-
-

About Cello Group

View Profile
Address
11-13 Charterhouse Buildings
London London & South East EC1M 7AP
United Kingdom
Employees -
Website http://cellogroup.co.uk
Updated 07/08/2019
Cello Health Plc is a global insight and strategic marketing group with a primary focus on the pharmaceutical and health sectors. It operates through two segments: Cello Health and Cello signal. The Cello Health segment provides market research, consulting, and communications services principally to its pharmaceutical and healthcare clients.